CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to MRK

TU2218 + KEYTRUDA® (Pembrolizumab)

Approved
MERCK (MRK)

Approved

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Dec '26
MRKPhase 2
✓Positive

TU2218 + KEYTRUDA® (Pembrolizumab) Phase 2 Est. Readout

TU2218 + KEYTRUDA® (Pembrolizumab)
Dec 2026~
CT.gov
Drug Information

Target Indication

Solid Tumor

Clinical Trial

NCT05784688

Last updated: 10/29/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.